ENDPOINTS

Kezar toplines small Phase 2a dataset in autoimmune liver disease

Kezar reported new data Tuesday morning from a small Phase 2a study in autoimmune hepatitis, or AIH, a condition where the immune system attacks the liver. The company tested its drug zetomipzomib in a 24 ...

Mar 25, 2025 - 16:00
 0
Kezar toplines small Phase 2a dataset in autoimmune liver disease
Kezar reported new data Tuesday morning from a small Phase 2a study in autoimmune hepatitis, or AIH, a condition where the immune system attacks the liver. The company tested its drug zetomipzomib in a 24 ...
Read More

Tags:

Previous Article

Smartphone Giant Vivo Announces ‘Vision’ MR Headset, Copying Apple’s Name & Design

Next Article

US Space Force celebrates return of 1st Guardian to launch to space (photos)

Related Posts

CRISPR startup Arbor Biotechnologies raises $73.9M as it nears first trial

CRISPR startup Arbor Biotechnologies raises $73.9M as i...

Mar 18, 2025  0

Eli Lilly seeks pitches from US states for slice of $27B manufacturing buildout 

Eli Lilly seeks pitches from US states for slice of $27...

Mar 5, 2025  0

Mallinckrodt and Endo exploring a $7B merger — report

Mallinckrodt and Endo exploring a $7B merger — report

Mar 12, 2025  0